Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin

Abstract

Background: This study investigated the influence of ADRB1 gene rs1801253 polymorphism on the treatment response of ticagrelor and aspirin in patients with acute coronary syndrome (ACS). Methods: Genetic typing was detected by Sanger sequencing. Platelet inhibition was assessed using thromboelastography. Kaplan–Meier and Cox regression were applied for prognosis analysis. Results: Out of 200 participants, 94 cases with rs1801253-CC genotype and 106 cases with CG+GG genotype were found. There was no significant difference between the rs1801253-CC and CG+GG groups in the number of ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction and unstable angina patients. There was no statistical difference in the basic data of patients in the two groups in terms of age, sex, medical history and medicine use in the dominant model. The rs1801253-CC genotype was a risk prognostic factor for ACS patients based on the Cox regression analysis results. Conclusion: Detecting ADRB1 polymorphism is crucial for ACS patients undergoing treatment with ticagrelor and aspirin.

Summary points

• There is a significant risk of ischemic and bleeding events in acute coronary syndrome patients on antiplatelet therapy, which is a hot research topic today.

• Platelet reactivity has individual differences and is related to genetic polymorphism.

• Previous evidence has determined the association of ADRB1 gene polymorphism with vascular injury and cardiovascular diseases such as ischemic stroke.

• The ADRB1 gene rs1801253 CC genotype carriers exhibited a poorer prognostic outcome compared with the CG/GG genotype carriers.

• ADRB1 polymorphisms did not correlate with the rate of platelet inhibition after ticagrelor.

Keywords: :

• acute coronary syndrome
• ADRB1 mutation
• platelet inhibition
• prognosis
• rs1801253

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the article. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they received People's Hospital of Rizhao Institutional Review Board approval or have followed the principles outlined in the Declaration of Helsinki for all human experimental investigations. In addition, for investigations involving human subjects, informed consent was obtained from the participants involved.